NeuroSense Completes Enrollment in Phase 2b ALS Clinical Trial

Go back to NeuroSense Completes Enrollment in Phase 2b ALS Clinical Trial
(NASDAQ: NRSN) Delayed: 3.07 --0 (-0%)
Previous Close $3.07    52 Week High $ 
Open $3.07    52 Week Low $ 
Day High $3.07    P/E N/A 
Day Low $3.07    EPS $ 
Volume 43,792